New Clinical Trials For Stage IV Breast Cancer
We added the following clinical trials to Metastatic Trial Search for January 2026. To see all clinical trials, please visit Metastatic Trial Search.
ER/PR Positive Trials
- GTAEXS617 for Advanced HR+ HER2- Breast Cancer
- Elacestrant Compared to Elacestrant Plus a CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer
- AVZO-023 Plus Hormone Therapy and an Experimental CDK2 Inhibitor for Advanced HR+, HER2- Breast Cancer
- Dato-DXd for Advanced HR+, HER2- Breast Cancer
- Palazestrant and Ribociclib Compared to Letrozole and Ribociclib for Advanced ER+, HER2- Breast Cancer
- Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer
Triple Negative Trials
- LY4175408 for Advanced Triple Negative Breast Cancer
- Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer
- PQ203 Peptide Drug-Conjugate for Advanced Triple Negative Breast Cancer